Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

153.00 -2.27 (-1.46%)
Streaming Delayed Price Updated: 1:57 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
51 52 Next >
News headline image
The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
News headline image
FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag ↗
Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price. 
Via Benzinga
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering ↗
GILEAD SCIENCES INC (NASDAQ:GILD) is a quality stock with strong profitability, high ROIC, and reasonable valuation, making it a candidate for long-term investors. 
Via Chartmill
News headline image
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention ↗
Analysts at Oppenheimer, BMO, Morgan Stanley, and Mizuho weighed in with positive long-term views, though Oppenheimer flagged near-term headwinds tied to court risks and cannibalization of existing... 
Via Stocktwits
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug ↗
The drug will sell under the brand name Yeztugo. In clinical testing, it kept 99.9% of patients from contracting HIV. 
Via Investor's Business Daily
News headline image
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report ↗
Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising concerns over global access and equity. 
Via Benzinga
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) – A potential undervalued opportunity in biopharma ↗
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability and reasonable growth, making it a candidate for value investors. The stock trades below industry averages on key valuation... 
Via Chartmill
News headline image
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased ↗
Jefferies thinks big pharma companies are "still on the hunt" for deals. 
Via Stocktwits
News headline image
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
News headline image
Why Gilead Scinces Stock Tumbled on Tuesday ↗
Via The Motley Fool
News headline image
Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes ↗
The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner. 
Via Stocktwits
News headline image
US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence ↗
The clinical hold is due to the identification of a safety signal, characterized by decreases in CD4+ T-cell (CD4) and absolute lymphocyte counts, in certain participants receiving the combination of... 
Via Stocktwits
News headline image
2 Reasons to Like GILD (and 1 Not So Much)
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as its stock price has climbed by 21% to $111.47 per share. This performance may... 
Via StockStory
Topics Stocks
News headline image
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug ↗
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S. PrEP users by 2035. 
Via Benzinga
News headline image
1 Healthcare Stock Worth Your Attention and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
Via StockStory
Topics Stocks
News headline image
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating ↗
The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. 
Via Stocktwits
News headline image
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance ↗
Gilead Chief Commercial Officer Johanna Mercier told Reuters that the company is eyeing a “global approach" to the launch of Lenacapavir. 
Via Stocktwits
Topics Government
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering ↗
GILEAD SCIENCES (NASDAQ:GILD) is a high-quality biopharma stock with strong profitability, efficient capital use, and attractive valuation, making it a candidate for long-term investors. 
Via Chartmill
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) – A Potentially Undervalued Biopharmaceutical Stock ↗
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability, a solid dividend, and reasonable growth potential, making it a candidate for value investors. 
Via Chartmill
News headline image
What Analysts Are Saying About Gilead Sciences Stock ↗
 
Via Benzinga
News headline image
What's going on in today's session: S&P500 movers ↗
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
Is the Market Bullish or Bearish on Gilead Sciences? ↗
 
Via Benzinga
News headline image
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
News headline image
Top S&P500 movers in Monday's pre-market session ↗
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
News headline image
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation ↗
US-China agree to slash tariffs by over 100%, easing fears of economic slowdown and inflation. Markets cheer with futures rising and yields up. 
Via Benzinga
Topics Economy World Trade
News headline image
GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance... 
Via StockStory
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.